AKAP 82 Activators
AKAP 82 Activators predominantly function by modulating the cAMP/PKA signaling axis, a crucial pathway in which AKAP 82 plays a significant role. Compounds like Forskolin, Rolipram, and IBMX enhance intracellular cAMP levels, either by directly activating adenylate cyclase or inhibiting phosphodiesterases like PDE4 and PDE3. This increase in cAMP concentrations leads to an enhanced activation of PKA, a kinase that AKAP 82 anchors at specific subcellular locations. The localization of PKA by AKAP 82 is critical for the specificity and efficiency of the kinase's action on various substrates. Therefore, by augmenting PKA activity, these compounds indirectly enhance the functional significance of AKAP 82.
Similarly, Sp-8-Br-cAMPS and Rp-8-Br-cAMPS, as cAMP analogs and antagonists, respectively, modulate PKA activity, thereby indirectly influencing AKAP 82's role. The Epac activator 007, though not directly influencing PKA, alters downstream signaling pathways that could indirectly impact AKAP 82's function in PKA localization. Brefeldin A and Okadaic Acid, while not directly involved in the cAMP/PKA pathway, affect cellular processes and phosphorylation states that can indirectly influence PKA activity and thus, AKAP 82's role.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an activator of adenylate cyclase, leading to increased cAMP levels. Elevated cAMP enhances PKA activity, which AKAP 82 anchors in specific cellular locations, thus indirectly enhancing AKAP 82's role in localizing PKA activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP. By preventing cAMP degradation, IBMX indirectly upregulates PKA activity, which is anchored by AKAP 82, thereby enhancing its functional role. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), leading to increased cAMP levels in cells. This elevation in cAMP indirectly augments PKA activity, a key enzyme localized by AKAP 82, thereby enhancing its function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus, which can influence signaling pathways involving PKA. This disruption may indirectly affect the function of AKAP 82 in localizing PKA. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases PP1 and PP2A. By altering phosphorylation states, it indirectly influences PKA activity and hence the role of AKAP 82 in anchoring PKA. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of phosphodiesterase 3 (PDE3), leading to increased cAMP levels and indirectly enhancing PKA activity, thereby affecting AKAP 82's role in PKA localization. | ||||||
Rp-8-Br-cAMPS | 129735-00-8 | sc-3539A sc-3539 | 500 µg 1 mg | $250.00 $340.00 | 22 | |
Rp-8-Br-cAMPS is a cAMP antagonist, which by inhibiting PKA, could lead to cellular compensations that enhance the functional role of AKAP 82 in PKA localization and regulation. | ||||||